Page last updated: 2024-08-16

risperidone and pergolide

risperidone has been researched along with pergolide in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's4 (50.00)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Ahman, M; Holmén, AG; Wan, H1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Sen, S; Sinha, N1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Brooks, D; Evans, SM; Levin, FR; McDowell, D; Nunes, EV; Spano, C1
Kesler, S; Niehaus, DJ; Seedat, S; Stein, DJ1
Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP1

Reviews

1 review(s) available for risperidone and pergolide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for risperidone and pergolide

ArticleYear
Pergolide mesylate for cocaine abuse: a controlled preliminary trial.
    The American journal on addictions, 1999,Spring, Volume: 8, Issue:2

    Topics: Adult; Cocaine-Related Disorders; Dopamine Agonists; Dopamine Antagonists; Double-Blind Method; Female; Humans; Male; Pergolide; Psychiatric Status Rating Scales; Risperidone; Single-Blind Method; Time Factors; Treatment Outcome

1999

Other Studies

6 other study(ies) available for risperidone and pergolide

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
    Depression and anxiety, 2000, Volume: 11, Issue:4

    Topics: Antipsychotic Agents; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Humans; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Risperidone; Treatment Outcome

2000
Cardiopulmonary complications of ergot-derivative dopamine agonists.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:10

    Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone

2004